In conclusion, we showed that IL12RB1 lacking exon two encodes a functional IL-12Rβ1. We demonstrated that Tcells can be highly efficiently transduced with AONs and are amenable to antisensemediated exon skipping. Furthermore, we showed that exon skipping (partly) corrects the IL-12Rβ1 deficiency in patients' cells.
Introduction
Human host immunity against pathogens is dependent on an effective cell- The infections in MSMD patients are difficult to treat, and are often recurrent. In patients with complete defects in these genes, the mortality before the age of 11 is high: IL-12p40, 31%; IL-12Rβ1, 10%; IFN-γR1, 27%; and STAT1, 100% 2 . Presently, there are no effective therapies for MSMD. Patients are treated with a long-term course of intense antibiotic therapy, which can be extended indefinitely to prevent new infections 3 . Some patients (with IL-12p40 or IL12Rβ1 defects) benefit
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A new approach to therapy for MSMD may be through correction of certain defects in the patients' RNA which can be achieved by a technique called exon 
Materials and Methods

Patients and controls
Cells were obtained from two unrelated patients with the same homozygous Q32X null mutation in IL-12Rβ1 due to a single nucleotide substitution (r.94C>T) in exon 2.
One of the patients has been described before as Patient 1 by de Jong et al 11 . Cells from healthy donors were used as controls. All research involving patient material was approved by the LUMC-Medical Ethical Committee under number P07.48.
IL-12Rβ1 and IL-23R expression constructs
Normal full-length IL12RB1 and IL23R coding sequences were cloned before into the expression vectors pLZRS-IRES-GFP and pLZRS-IRES-ΔNGFR respectively 12;13 .
IL12RB1 lacking exon 2 was introduced in the construct by site-directed mutagenesis 14 . As negative controls vectors without insert were applied. Helper-free recombinant retrovirus was produced after introducing the constructs into a 293T-based amphotropic retroviral packaging cell line, Phoenix 15 using a calcium-phosphate transfection kit (Invitrogen). The virus producing cells were subsequently cultured for 2 weeks under 2 μ g/ml puromycin (Clontech) selection after which a 20 h supernatant was harvested.
Cells, culture conditions and retroviral transduction of expression constructs
Peripheral blood monocytes (PBMCs) were isolated from heparinized blood by Ficoll-Amidotrizoate density gradient centrifugation. Cells were cultured in IMDM (Bio-Whittaker) supplemented with 20 mM GlutaMAX (Gibco-BRL), 10% FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin (Gibco-BRL) and 30 U/ml IL-2 (Chiron). 
FACS and functional analyses of expression constructs
Cells were labeled directly with PE-conjugated mouse anti-human IL-12Rβ1 mAb 
AON design and chemistry
AONs were designed to target exonic splice enhancers (ESEs), the sequences within an exon that are recognized by splicing factors to include an exon in a transcript. The locations of potential ESEs were predicted by ESEfinder (rulai.cshl.edu/tools/ESE/) 17 . The secondary structure of the pre-mRNA, as predicted by M-FOLD (http://frontend.bioinfo.rpi.edu/applications/mfold/) 18 , was also taken into account. was also available with a 5'FAM label (Prosensa).
Cell culture and transduction of AONs
Peripheral blood monocytes (PBMCs) were isolated from heparinized blood by supplemented with 20 mM GlutaMAX (Gibco-BRL), 10% FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin, with 2 μ g/ml anti-CD2, 2 μ g/ml anti-CD28, 1000 pg/ml IL-12 (R&Dsystems), and/or 75 ng/ml IL-18 (Biosource). To measure cytokine production supernatant of each well was removed after two to six days. The concentrations of IFN-γ were determined by cytokine-specific ELISAs (Biosource).
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Results
IL-12Rβ1 construct lacking exon two is expressed on the membrane
To determine feasibility of exon skipping for correction of MSMD we chose to test the technique in cells from two unrelated patients with the same complete IL-12Rβ1 deficiency. Both patients harbor homozygous single nucleotide substitutions (r.94C>T) in exon two of the IL12RB1 gene resulting in a premature stop of protein translation (Q32X). First, we determined whether IL-12Rβ1 lacking exon two would be a functional protein. Hereto, an IL12RB1 expression construct lacking exon two was generated by altering a wild-type IL12RB1 expression construct that we reported before 12 . The constructs were made in the retroviral expression vector pLZRS which ensures that the IL12RB1 and GFP genes are transcribed and expressed in tandem, and allows for selection of transduced cells by FACS sorting on GFP signal.
Constructs were transduced into activated T-cells from the patients, as a negative control the pLZRS vector without insert was used.
We analyzed expression of the IL-12Rβ1 on the cell surface with four IL-12Rβ1 antibodies. In untransduced cells from a patient no GFP signal is detected and with the antibody DU-1 (raised against full-length IL-12Rβ1) no expression of IL-12Rβ1 is detected on the cell surface ( Figure 1A 
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high intensity of fluorescence was detectable twenty-four hours after nucleofection ( Figure 3C ).
Nucleofection of AONs results in exon skipping
RNA was isolated at 24 h after nucleofection of various AONs into activated T-cells of a normal control and of patients to determine whether exon skipping had occurred in the pre-mRNA. Transcripts were analyzed with a primerset that can detect normally spliced transcripts (443 bp) as well as transcripts in which exon two is spliced out (383 bp). In control cells the most abundant PCR product was 443 bp, while a 383 bp product was usually also detectable, indicating exon skipping occurred, but at a low efficiency ( Figure 4) . In patient cells with nucleofection but without AON always only a 443 bp product was present (Figure 4 ). Also when using primers designed specifically to detect the exon skipped transcript (i.e. forward primer 1/3F directed at the junction of exon 1 and 3) no PCR product was detectable in these cells (data not shown). In patient cells nucleofected with various AONs the most abundant PCR product was usually of 383 bp although variation between effectiveness was clear ( Figure 4) . Several of the 383 bp products were isolated from gel and sequenced, these all revealed splicing directly from exon one to exon three, lacking the 60 bp of exon two. Transcripts of the household gene GAPDH were analyzed in all samples to allow comparison of total RNA present, GAPDH PCR products appeared not to differ between samples (data not shown). To determine whether any additional exons were unintentionally skipped full-length IL12RB1 PCR products, generated with primers annealing to exon 1 (primer 1F) and exon 17 (primer 17R), were analyzed as well. No other transcripts were however detected (data not shown).
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Three AONs (AON02, AON03 and AON64) were directed at sequences in exon two that were identical in patients and controls. Two AONs (AON01 and AON63) were specifically directed at wild-type sequences, AON128 was directed specifically at sequences in the patient cells. AON64 did not have an effect on splicing in any of the cells, all other AONs had comparable effects on splicing, except for AON03 which, in patient cells, always showed a stronger effect. Combinations of non-overlapping AONs (AON02/03, AON128/02) worked better than single AONs in both control and patient cells (Figure 4) .
Exon skipping results in correction of IL-12Rβ1 expression on the cell surface
To determine whether exon skipping resulted in IL-12Rβ1 expression on the cell surface, cells were labeled with antibodies against IL-12Rβ1 or with an isotype control and analyzed by FACS. In cells nucleofected without AON no IL-12Rβ1 expression was detected on the cell surface ( Figure 5B ). In cells nucleofected with AONs IL-12Rβ1 expression could be detected on the cell surface as early as 24 h after nucleofection ( Figure 5D , 5F, 5H), while cells labeled with an isotype control ( Figure   5A , 5C, 5E, 5G) showed that this was not due to aspecific staining.
Exon skipping results in functional correction of the IL-12Rβ1 defect
Efficient exon skipping is, based on the results above with expression constructs, expected to (at least partly) restore the function of the IL-12Rβ1 in the targeted cells. 
Discussion
Patients with complete defects of one of the genes involved in the type-1 cytokine pathway suffer from severe, life-threatening infections with otherwise non-pathogenic mycobacteria and salmonellae. For these patients no effective therapy is available. We have shown here, with a specific IL-12Rβ1 defect as example, that antisense-mediated exon skipping may in the future provide an additional therapeutic option for a selection of these patients.
Antisense-mediated exon skipping is a technique that has been shown to achieve phenotypical correction of certain genetic defects in vitro [5] [6] [7] and in vivo 10 . The success of this technique is highly dependent on the cell type targeted, the transfection efficiency, the sequences targeted and very important; on whether the protein missing certain exon(s) is properly expressed and is (partly) functional. The cells we target here, T-cells, are readily available from the blood from patients and controls. The transfection efficiency in these cells is, at 96%, very high. The sequence we target, in exon 2 of the IL12RB1, proved amenable to antisense-mediated exon skipping.
Moreover, the exon skipping appears to be more efficient in patient cells than in controls cells. This is likely due to the effect the mutation has on one of the predicted exonic splice enhancers (ESE). According to the program ESEfinder 17 two of the nine predicted ESE motifs in exon two; an Srp40 and a Sc35 motif, are obliterated due to the mutation. Normally, splicing factors bind to ESEs and recruit splicing machinery to actively include an exon in a transcript. The obliterated Sc35 motif has the highest score of the nine ESE motifs in exon two. Unfortunately for these two patients, the disruption of the two ESEs by the mutation is not enough to induce exon The great advantage of exon skipping to correct IL-12Rβ1 deficiency in patients is that the lymphocytes can be treated ex vivo and are in easily accessible tissue for treatment in vivo if desired. In addition, treatment may be only needed during infections with mycobacteria or salmonellae and may result in permanent protection if memory T-cells can be generated effectively. A drawback of antisensemediated exon skipping is that AONs, although they can be detected for 3-4 weeks after delivery 20 , are diluted when cells divide, thus reducing the duration of the effect.
A potential pitfall is that antibodies may be generated against the corrected IL-12Rβ1
protein, similar to the antibodies generated in 10-30% of the hemophilia patients that receive factor VIII 21 . If antibodies should be generated, the expression of IL-12Rβ1 is entirely reversible due to the limited life-span of the lymphocytes.
Apart from the two patients in this study skipping of exon 2 would be possible in at least four other patients with defects in exon 2; patients 17.II. and subsequently stimulated for 6 days with 75 ng/ml IL-18 or 5000 ng/ml IL-12 or 5000 ng/ml IL-12 and 75 ng/ml IL-18. IFN-γ production was analyzed by ELISA.
The bars represent averages of an experiment performed in duplo.
